To announce the FDA approval of cefepime and zidebactam for treating complicated urinary tract infections in adults, as stated in a Wockhardt press release.
Key Findings:
Cefepime and zidebactam achieved a composite clinical cure and microbiologic response rate of 89% at the test-of-cure visit, as reported by Wockhardt.
This rate was significantly higher compared to 68% for meropenem, according to Wockhardt.
The treatment was generally well tolerated, as stated in the Wockhardt press release.
Interpretation:
Cefepime and zidebactam combines a fourth-generation cephalosporin with a non-beta-lactam antibacterial and beta-lactamase inhibitor, acting synergistically.
Limitations:
The study was limited to patients with complicated urinary tract infections or acute pyelonephritis, as noted by Wockhardt.
Conclusion:
Cefepime and zidebactam is indicated for infections caused by susceptible strains of specific Gram-negative pathogens, according to Wockhardt.
